Oncology Companion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product ( Instrument, Consumable, Software ); Technology ( Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In Situ Hybridization (ISH)/Fluorescence in Situ Hybridization (FISH), Other Technologies ); Disease Type ( Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia, Melanoma, Prostate Cancer, Others ); End User ( Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center )

Report Code: TIPRE00022282 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

A companion diagnostic test is used to match a patient to a specific therapy or drug. An oncology companion diagnostic test identifies patient's genetic change or biomarker that is targeted by the drug.

MARKET SCOPE

The "Global Oncology Companion Diagnostics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oncology companion diagnostics market with detailed market segmentation by product, technology, disease type, end user, and geography. The report provides key statistics on the market status of the leading oncology companion diagnostics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on product, the global oncology companion diagnostics market is segmented into instrument, consumable, and software.
  •   On the basis of technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), and other technologies.
  •   Based on disease type, the market is bifurcated into breast cancer, non-small cell lung cancer, colorectal cancer, leukemia, melanoma, prostate cancer, and others.
  •   On the basis of end user, the market is segmented into hospital, pathology/diagnostic laboratory, and academic medical center.

MARKET DYNAMICS

Drivers-


  •   Increasing number of FDA approvals for CDx assay.
  •   Rising prevalence of cancer.
  •   Benefits offered by oncology Companion Diagnostics (CDx) assays.

Restraints-

  •   High cost of cancer companion diagnostics tests

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oncology companion diagnostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Oncology companion diagnostics market in these regions.

IMPACT OF COVID-19 ON ONCOLOGY COMPANION DIAGNOSTICS MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and medical industry in various countries due to lockdowns, travel bans, and business shutdowns. Various medical devices companies have shut down their productions, hence are unable to manufacture to meet the rising demand. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, COVID?19 pandemic caused damage in health care in terms of reduced hospital admissions or postponed treatment of patients suffering from other acute or chronic diseases. Further, In the United States, many doctors, hospitals and other healthcare facilities are delaying or canceling the cancer procedures, surgeries and sometimes screenings or other treatments, if it is not considered urgent, emergencies, or otherwise indicated for life-threatening conditions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the oncology companion diagnostics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from oncology companion diagnostics market are anticipated to lucrative growth opportunities in the future with the rising demand for oncology companion diagnostics in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oncology companion diagnostics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Qiagen
  •   Illumina
  •   F. Hoffmann-La Roche Ltd.
  •   Thermo Fisher Scientific, Inc
  •   Agilent Technologies, Inc.
  •   Arup Laboratories
  •   Abbott
  •   Myriad Genetics, Inc
  •   Biomérieux SA
  •   Invivoscribe

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oncology Companion Diagnostics Market - By Product
1.3.2 Oncology Companion Diagnostics Market - By Technology
1.3.3 Oncology Companion Diagnostics Market - By Disease Type
1.3.4 Oncology Companion Diagnostics Market - By End User
1.3.5 Oncology Companion Diagnostics Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ONCOLOGY COMPANION DIAGNOSTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ONCOLOGY COMPANION DIAGNOSTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ONCOLOGY COMPANION DIAGNOSTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ONCOLOGY COMPANION DIAGNOSTICS - GLOBAL MARKET OVERVIEW
6.2. ONCOLOGY COMPANION DIAGNOSTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. INSTRUMENT
7.3.1. Overview
7.3.2. Instrument Market Forecast and Analysis
7.4. CONSUMABLE
7.4.1. Overview
7.4.2. Consumable Market Forecast and Analysis
7.5. SOFTWARE
7.5.1. Overview
7.5.2. Software Market Forecast and Analysis
8. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. POLYMERASE CHAIN REACTION (PCR)
8.3.1. Overview
8.3.2. Polymerase Chain Reaction (PCR) Market Forecast and Analysis
8.4. NEXT-GENERATION SEQUENCING (NGS)
8.4.1. Overview
8.4.2. Next-Generation Sequencing (NGS) Market Forecast and Analysis
8.5. IMMUNOHISTOCHEMISTRY (IHC)
8.5.1. Overview
8.5.2. Immunohistochemistry (IHC) Market Forecast and Analysis
8.6. IN SITU HYBRIDIZATION (ISH)/FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.6.1. Overview
8.6.2. In Situ Hybridization (ISH)/Fluorescence in Situ Hybridization (FISH) Market Forecast and Analysis
8.7. OTHER TECHNOLOGIES
8.7.1. Overview
8.7.2. Other Technologies Market Forecast and Analysis
9. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
9.1. OVERVIEW
9.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
9.3. BREAST CANCER
9.3.1. Overview
9.3.2. Breast Cancer Market Forecast and Analysis
9.4. NON-SMALL CELL LUNG CANCER
9.4.1. Overview
9.4.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
9.5. COLORECTAL CANCER
9.5.1. Overview
9.5.2. Colorectal Cancer Market Forecast and Analysis
9.6. LEUKEMIA
9.6.1. Overview
9.6.2. Leukemia Market Forecast and Analysis
9.7. MELANOMA
9.7.1. Overview
9.7.2. Melanoma Market Forecast and Analysis
9.8. PROSTATE CANCER
9.8.1. Overview
9.8.2. Prostate Cancer Market Forecast and Analysis
9.9. OTHERS
9.9.1. Overview
9.9.2. Others Market Forecast and Analysis
10. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITAL
10.3.1. Overview
10.3.2. Hospital Market Forecast and Analysis
10.4. PATHOLOGY/DIAGNOSTIC LABORATORY
10.4.1. Overview
10.4.2. Pathology/Diagnostic Laboratory Market Forecast and Analysis
10.5. ACADEMIC MEDICAL CENTER
10.5.1. Overview
10.5.2. Academic Medical Center Market Forecast and Analysis
11. ONCOLOGY COMPANION DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Oncology Companion Diagnostics Market Overview
11.1.2 North America Oncology Companion Diagnostics Market Forecasts and Analysis
11.1.3 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.1.4 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.1.5 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.1.6 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.1.7 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.1.7.1 United States Oncology Companion Diagnostics Market
11.1.7.1.1 United States Oncology Companion Diagnostics Market by Product
11.1.7.1.2 United States Oncology Companion Diagnostics Market by Technology
11.1.7.1.3 United States Oncology Companion Diagnostics Market by Disease Type
11.1.7.1.4 United States Oncology Companion Diagnostics Market by End User
11.1.7.2 Canada Oncology Companion Diagnostics Market
11.1.7.2.1 Canada Oncology Companion Diagnostics Market by Product
11.1.7.2.2 Canada Oncology Companion Diagnostics Market by Technology
11.1.7.2.3 Canada Oncology Companion Diagnostics Market by Disease Type
11.1.7.2.4 Canada Oncology Companion Diagnostics Market by End User
11.1.7.3 Mexico Oncology Companion Diagnostics Market
11.1.7.3.1 Mexico Oncology Companion Diagnostics Market by Product
11.1.7.3.2 Mexico Oncology Companion Diagnostics Market by Technology
11.1.7.3.3 Mexico Oncology Companion Diagnostics Market by Disease Type
11.1.7.3.4 Mexico Oncology Companion Diagnostics Market by End User
11.2. EUROPE
11.2.1 Europe Oncology Companion Diagnostics Market Overview
11.2.2 Europe Oncology Companion Diagnostics Market Forecasts and Analysis
11.2.3 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.2.4 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.2.5 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.2.6 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.2.7 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Oncology Companion Diagnostics Market
11.2.7.1.1 Germany Oncology Companion Diagnostics Market by Product
11.2.7.1.2 Germany Oncology Companion Diagnostics Market by Technology
11.2.7.1.3 Germany Oncology Companion Diagnostics Market by Disease Type
11.2.7.1.4 Germany Oncology Companion Diagnostics Market by End User
11.2.7.2 France Oncology Companion Diagnostics Market
11.2.7.2.1 France Oncology Companion Diagnostics Market by Product
11.2.7.2.2 France Oncology Companion Diagnostics Market by Technology
11.2.7.2.3 France Oncology Companion Diagnostics Market by Disease Type
11.2.7.2.4 France Oncology Companion Diagnostics Market by End User
11.2.7.3 Italy Oncology Companion Diagnostics Market
11.2.7.3.1 Italy Oncology Companion Diagnostics Market by Product
11.2.7.3.2 Italy Oncology Companion Diagnostics Market by Technology
11.2.7.3.3 Italy Oncology Companion Diagnostics Market by Disease Type
11.2.7.3.4 Italy Oncology Companion Diagnostics Market by End User
11.2.7.4 Spain Oncology Companion Diagnostics Market
11.2.7.4.1 Spain Oncology Companion Diagnostics Market by Product
11.2.7.4.2 Spain Oncology Companion Diagnostics Market by Technology
11.2.7.4.3 Spain Oncology Companion Diagnostics Market by Disease Type
11.2.7.4.4 Spain Oncology Companion Diagnostics Market by End User
11.2.7.5 United Kingdom Oncology Companion Diagnostics Market
11.2.7.5.1 United Kingdom Oncology Companion Diagnostics Market by Product
11.2.7.5.2 United Kingdom Oncology Companion Diagnostics Market by Technology
11.2.7.5.3 United Kingdom Oncology Companion Diagnostics Market by Disease Type
11.2.7.5.4 United Kingdom Oncology Companion Diagnostics Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Oncology Companion Diagnostics Market Overview
11.3.2 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis
11.3.3 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.3.4 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.3.5 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.3.6 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Oncology Companion Diagnostics Market
11.3.7.1.1 Australia Oncology Companion Diagnostics Market by Product
11.3.7.1.2 Australia Oncology Companion Diagnostics Market by Technology
11.3.7.1.3 Australia Oncology Companion Diagnostics Market by Disease Type
11.3.7.1.4 Australia Oncology Companion Diagnostics Market by End User
11.3.7.2 China Oncology Companion Diagnostics Market
11.3.7.2.1 China Oncology Companion Diagnostics Market by Product
11.3.7.2.2 China Oncology Companion Diagnostics Market by Technology
11.3.7.2.3 China Oncology Companion Diagnostics Market by Disease Type
11.3.7.2.4 China Oncology Companion Diagnostics Market by End User
11.3.7.3 India Oncology Companion Diagnostics Market
11.3.7.3.1 India Oncology Companion Diagnostics Market by Product
11.3.7.3.2 India Oncology Companion Diagnostics Market by Technology
11.3.7.3.3 India Oncology Companion Diagnostics Market by Disease Type
11.3.7.3.4 India Oncology Companion Diagnostics Market by End User
11.3.7.4 Japan Oncology Companion Diagnostics Market
11.3.7.4.1 Japan Oncology Companion Diagnostics Market by Product
11.3.7.4.2 Japan Oncology Companion Diagnostics Market by Technology
11.3.7.4.3 Japan Oncology Companion Diagnostics Market by Disease Type
11.3.7.4.4 Japan Oncology Companion Diagnostics Market by End User
11.3.7.5 South Korea Oncology Companion Diagnostics Market
11.3.7.5.1 South Korea Oncology Companion Diagnostics Market by Product
11.3.7.5.2 South Korea Oncology Companion Diagnostics Market by Technology
11.3.7.5.3 South Korea Oncology Companion Diagnostics Market by Disease Type
11.3.7.5.4 South Korea Oncology Companion Diagnostics Market by End User
11.3.7.6 Rest of Asia-Pacific Oncology Companion Diagnostics Market
11.3.7.6.1 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Product
11.3.7.6.2 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Technology
11.3.7.6.3 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Disease Type
11.3.7.6.4 Rest of Asia-Pacific Oncology Companion Diagnostics Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Oncology Companion Diagnostics Market Overview
11.4.2 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis
11.4.3 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.4.4 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.4.5 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.4.6 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Oncology Companion Diagnostics Market
11.4.7.1.1 South Africa Oncology Companion Diagnostics Market by Product
11.4.7.1.2 South Africa Oncology Companion Diagnostics Market by Technology
11.4.7.1.3 South Africa Oncology Companion Diagnostics Market by Disease Type
11.4.7.1.4 South Africa Oncology Companion Diagnostics Market by End User
11.4.7.2 Saudi Arabia Oncology Companion Diagnostics Market
11.4.7.2.1 Saudi Arabia Oncology Companion Diagnostics Market by Product
11.4.7.2.2 Saudi Arabia Oncology Companion Diagnostics Market by Technology
11.4.7.2.3 Saudi Arabia Oncology Companion Diagnostics Market by Disease Type
11.4.7.2.4 Saudi Arabia Oncology Companion Diagnostics Market by End User
11.4.7.3 U.A.E Oncology Companion Diagnostics Market
11.4.7.3.1 U.A.E Oncology Companion Diagnostics Market by Product
11.4.7.3.2 U.A.E Oncology Companion Diagnostics Market by Technology
11.4.7.3.3 U.A.E Oncology Companion Diagnostics Market by Disease Type
11.4.7.3.4 U.A.E Oncology Companion Diagnostics Market by End User
11.4.7.4 Rest of Middle East and Africa Oncology Companion Diagnostics Market
11.4.7.4.1 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Product
11.4.7.4.2 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Technology
11.4.7.4.3 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Disease Type
11.4.7.4.4 Rest of Middle East and Africa Oncology Companion Diagnostics Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Oncology Companion Diagnostics Market Overview
11.5.2 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis
11.5.3 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.5.4 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.5.5 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.5.6 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.5.7 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Oncology Companion Diagnostics Market
11.5.7.1.1 Brazil Oncology Companion Diagnostics Market by Product
11.5.7.1.2 Brazil Oncology Companion Diagnostics Market by Technology
11.5.7.1.3 Brazil Oncology Companion Diagnostics Market by Disease Type
11.5.7.1.4 Brazil Oncology Companion Diagnostics Market by End User
11.5.7.2 Argentina Oncology Companion Diagnostics Market
11.5.7.2.1 Argentina Oncology Companion Diagnostics Market by Product
11.5.7.2.2 Argentina Oncology Companion Diagnostics Market by Technology
11.5.7.2.3 Argentina Oncology Companion Diagnostics Market by Disease Type
11.5.7.2.4 Argentina Oncology Companion Diagnostics Market by End User
11.5.7.3 Rest of South and Central America Oncology Companion Diagnostics Market
11.5.7.3.1 Rest of South and Central America Oncology Companion Diagnostics Market by Product
11.5.7.3.2 Rest of South and Central America Oncology Companion Diagnostics Market by Technology
11.5.7.3.3 Rest of South and Central America Oncology Companion Diagnostics Market by Disease Type
11.5.7.3.4 Rest of South and Central America Oncology Companion Diagnostics Market by End User
12. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ONCOLOGY COMPANION DIAGNOSTICS MARKET
12.1 North America
12.2 Europe
12.3 Asia-Pacific
12.4 Middle East and Africa
12.5 South and Central America
13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
14. ONCOLOGY COMPANION DIAGNOSTICS MARKET, KEY COMPANY PROFILES
14.1. QIAGEN
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. ILLUMINA, INC.
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. F. HOFFMANN-LA ROCHE LTD.
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. THERMO FISHER SCIENTIFIC, INC.
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. AGILENT TECHNOLOGIES, INC.
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. ARUP LABORATORIES
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. ABBOTT
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. MYRIAD GENETICS, INC
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. BIOMéRIEUX SA
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. INVIVOSCRIBE, INC.
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments
15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS


* Above given report scope is tentative, and may change during the study process as per the research requirement.
* List of companies provided under ‘Company Profile’ chapter is tentative and may change during the course of the study. This list is customizable as per the client requirements.
* Financial information would be provided only for the public companies.
The List of Companies

1. Qiagen
2. Illumina
3. F. Hoffmann-La Roche Ltd.
4. Thermo Fisher Scientific, Inc
5. Agilent Technologies, Inc.
6. Arup Laboratories
7. Abbott
8. Myriad Genetics, Inc
9. Biomérieux SA
10. Invivoscribe
TIPRE00022282
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking